Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 1:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 707 matching trials from the live ClinicalTrials.gov search.
Filters: "mild cognitive impairment" Condition: Alzheimer's Disease Clear all
Completed Phase 2 Interventional Results available

Riluzole in Mild Alzheimer's Disease

NCT01703117
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Riluzole, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
50 Years to 95 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Light Exposure Tracker Designed to Improve Circadian Rhythms - Aim 1

NCT06356337
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Light goggles, Daily reminder test message
Device · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Menands, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Prevention of Depression in Spouses of People With Cognitive Impairment

NCT00321971
View directory record Official record
Conditions
Depression
Interventions
PST-MCI/AD Caregiving, NT-MCI/AD Caregiving
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 14, 2026, 1:50 AM EDT
Enrolling by invitation No phase listed Observational

Expanding Access to Cognitive Health Biomarker Testing at Home

NCT07594665
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Alzheimer's Dementia (AD), Subjective Cognitive Decline (SCD), Cognitive Aging
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Terminated Phase 2 Interventional Results available

Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease

NCT02503501
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease (AD)
Interventions
Insulin glulisine, Placebo
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074

NCT01303744
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
CHF 5074 1x, CHF 5074 2x, CHF 5074 3x, Placebo
Drug
Lead sponsor
CERESPIR
Industry
Eligibility
18 Years to 79 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
St. Petersburg, Florida • Eatontown, New Jersey • Monroe Twp, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 14, 2026, 1:50 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Negotiation Training for Family Caregivers of People With Alzheimer's Disease

NCT07859540
View directory record Official record
Conditions
Alzheimer's Disease (AD), Dementia, Cognitive Impairment
Interventions
NegotiAge, PlanYourLifespan
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Rhythmically Entrained Exercise in Community-Dwelling Older Adults

NCT05462977
View directory record Official record
Conditions
Exercise, Gait, Cognitive Decline, Caregiver Burden, Cognitive Impairment, Dementia, Alzheimer Disease, Mild Cognitive Impairment, Respite Care, Mental Health, Depression, Music Therapy, Psychosocial Intervention, Cognition, Geriatric Assessment, Cognitive Dysfunction, Cognitive Aging, Outcome Assessment, Health Care, Balance, Fall, Walking, Affect, Physical Exertion, Memory Deficit, Memory Disorders, Memory Impairment, Neuropsychological Tests, Executive Function, Middle Aged, Healthy Aging, Elderly
Interventions
Group exercise program
Behavioral
Lead sponsor
University of North Carolina, Greensboro
Other
Eligibility
55 Years to 99 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease

NCT02560753
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
T3D-959
Drug
Lead sponsor
T3D Therapeutics, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Delray Beach, Florida • Miami, Florida • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

Effect of Insulin Sensitizer Metformin on AD Biomarkers

NCT01965756
View directory record Official record
Conditions
Alzheimer's Disease, Vascular Dementia, Dementia, Memory Impairment
Interventions
Metformin, Placebos
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 14, 2026, 1:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study To Assess The Feasibility Of Indivi Mobile Application In Monitoring Cognitive Performance In Aging Population

NCT07174869
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Mild Alzheimer Disease
Interventions
Not listed
Lead sponsor
Indivi AG
Industry
Eligibility
50 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Not listed Phase 2 Interventional

Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease

NCT01811381
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Curcumin, aerobic yoga, non aerobic yoga, Placebo
Drug · Behavioral · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2020 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Imaging Inflammation in Alzheimer's Disease

NCT02831283
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
11C-PBR28, 18F-Florbetaben, Lumbar puncture (optional)
Drug · Procedure
Lead sponsor
Patrick Lao
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 14, 2026, 1:50 AM EDT
Active, not recruiting Not applicable Interventional

Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease

NCT05417555
View directory record Official record
Conditions
Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Deep Brain Stimulation, Mild Alzheimer's Disease
Interventions
Low-Intensity Focused Ultrasound Pulsation (LIFUP)
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

NCT01148498
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
solanezumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Not applicable Interventional Results available

Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment

NCT02155946
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 88 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting Phase 2 Interventional

Alzheimer's Tau Platform: Master Protocol

NCT06957418
View directory record Official record
Conditions
Preclinical Alzheimer's Disease, Alzheimer Disease, Prodromal Alzheimer's Disease
Interventions
AADvac1, Tau2
Drug
Lead sponsor
Paul S. Aisen
Other
Eligibility
50 Years to 80 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
San Francisco, California • Providence, Rhode Island • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MIND Diet Intervention and Cognitive Decline

NCT02817074
View directory record Official record
Conditions
Cognitive Decline, Dementia, Alzheimer Disease, Vascular Dementia
Interventions
MIND Diet, Mild Weight Loss
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
65 Years to 84 Years
Enrollment
604 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 14, 2026, 1:50 AM EDT
Completed No phase listed Observational

Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

NCT01465360
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia, Primary Progressive Aphasia, Parkinson' Disease Dementia, Mixed Dementia
Interventions
Not listed
Lead sponsor
Exonhit
Industry
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
3
States / cities
Las Vegas, Nevada • Cleveland, Ohio • Lakewood, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2012 · Synced Oct 14, 2026, 1:50 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults

NCT07392723
View directory record Official record
Conditions
Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of, Brain Aging, Fatty Acids, Omega-3
Interventions
Alpha-Linolenic Acid (2.6 g/day), Placebo Control Group
Drug · Dietary Supplement
Lead sponsor
Michal Schnaider Beeri, Ph.D.
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 14, 2026, 1:50 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension

NCT04937959
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer's Disease (Incl Subtypes), Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Mild Cognitive Impairment, Normal Cognition
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Phase 2 Interventional Results available

A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease

NCT00710684
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SB-742457 15mg, SB-742457 35mg, Placebo, donepezil 5-10mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 85 Years
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Litchfield Park, Arizona • Fresno, California • Rancho Mirage, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 14, 2026, 1:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Synaptic Injury and Functional Connectivity in Alzheimer's Disease

NCT03300726
View directory record Official record
Conditions
Alzheimer Disease, Late Onset
Interventions
CSF analysis, Functional MRI
Diagnostic Test · Radiation
Lead sponsor
Ohio State University
Other
Eligibility
60 Years to 95 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 14, 2026, 1:50 AM EDT
Completed Not applicable Interventional Results available

Effect of Blueberry Supplementation on Alzheimer's Biomarkers

NCT05172128
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease
Interventions
lyophilized blueberry supplement
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
55 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 14, 2026, 1:50 AM EDT